ATOPIC DERMATITIS MARKET ANALYSIS

Atopic Dermatitis Market, By Drug Class (Corticosteroids, Emollients/Moisturizers, IL-4 & PDE4 Inhibitors, Calcineurin Inhibitors Antibiotics, and Other Drug Classes), By Type of Administration (Topical, Oral, and Injectable), By Prescription Type (Over-the-counter (OTC) and Prescription), and By Geography (North America, Europe, Asia Pacific, Middle East and Africa, and Latin America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Jan 2023
Code : CMI712
Pages :170
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Atopic Dermatitis Market: Key Developments

In August 2022, Chugai Pharmaceutical Co., Ltd. announced that Maruho Co., Ltd. announced the launch of anti-IL-31 receptor A humanized monoclonal antibody Mitchga Subcutaneous Injection for the treatment of itching associated with atopic dermatitis. Mitchga is approved by the Ministry of Health, Labour and Welfare (MHLW) on March 28, 2022.

In June 2022, Otsuka Pharmaceutical Co. (Otsuka) announced the launch of Moizerto Ointment (difamilast), a new treatment for atopic dermatitis in Japan.

In February 2022, the U.S. Food and Drug Administration (USFDA) approved the use of Opzelura (ruxolitinib) cream for the topical treatment of mild to moderate atopic dermatitis. They noted that it's for the short-term, non-continuous treatment of chronic atopic dermatitis.

In May 2020, the U.S. FDA approved Dupixent (dupilumab) for children aged six to 11 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.